SUPN Supernus Pharmaceuticals Inc

$48.04

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/2/2025

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.

Website: https://www.supernus.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1356576
Address
1550 E GUDE DR, ROCKVILLE, MD, US
Valuation
Market Cap
$1.72B
P/E Ratio
23.30
PEG Ratio
1.47
Price to Book
1.66
Performance
EPS
$1.32
Dividend Yield
—
Profit Margin
11.20%
ROE
7.55%
Technicals
50D MA
$33.19
200D MA
$33.81
52W High
$40.28
52W Low
$25.53
Fundamentals
Shares Outstanding
56M
Target Price
$38.80
Beta
0.90

SUPN EPS Estimates vs Actual

● Estimated
● Actual

SUPN News & Sentiment

Sep 26, 2025 • Zacks Commentary NEUTRAL
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Sep 25, 2025 • Zacks Commentary BULLISH
Are You Looking for a Top Momentum Pick? Why Supernus Pharmaceuticals ( SUPN ) is a Great Choice
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Sep 23, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Supernus Pharmaceuticals, Inc. ( SUPN ) Hit a 52 Week High, Can the Run Continue?
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Sep 18, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Biogen Gets EU Nod for First Postpartum Depression Drug
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
Sep 17, 2025 • Benzinga NEUTRAL
Biogen Receives European Commission Approval for ZURZUVAE® ( zuranolone ) , the First and Only Treatment Approved for Women with Postpartum Depression in Europe - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Biogen ( NASDAQ:BIIB )
Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum depressive symptoms6-11
Sep 17, 2025 • GlobeNewswire NEUTRAL
Biogen Receives European Commission Approval for ZURZUVAE® ( zuranolone ) , the First and Only Treatment Approved for Women with Postpartum Depression in Europe
CAMBRIDGE, Mass., Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced that the European Commission ( EC ) has granted marketing authorization for ZURZUVAE® ( zuranolone ) to treat post-partum depression ( PPD ) in adults following childbirth.
Sentiment Snapshot

Average Sentiment Score:

0.131
50 articles with scored sentiment

Overall Sentiment:

Neutral

SUPN Reported Earnings

Feb 25, 2025
Dec 31, 2024 (Pre market)
0.03 Surprise
  • Reported EPS: $0.55
  • Estimate: $0.52
  • Whisper: —
  • Surprise %: 5.4%
Nov 04, 2024
Sep 30, 2024 (Post market)
0.25 Surprise
  • Reported EPS: $0.69
  • Estimate: $0.44
  • Whisper: —
  • Surprise %: 56.8%
Aug 06, 2024
Jun 30, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $0.36
  • Estimate: $0.31
  • Whisper: —
  • Surprise %: 16.1%
May 08, 2024
Mar 31, 2024 (Post market)
-0.12 Surprise
  • Reported EPS: $0.26
  • Estimate: $0.38
  • Whisper: —
  • Surprise %: -31.6%
Feb 27, 2024
Dec 31, 2023 (Post market)
0.34 Surprise
  • Reported EPS: $0.89
  • Estimate: $0.55
  • Whisper: —
  • Surprise %: 61.8%
Nov 08, 2023
Sep 30, 2023 (Post market)
0.16 Surprise
  • Reported EPS: $0.24
  • Estimate: $0.08
  • Whisper: —
  • Surprise %: 200.0%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.21 Surprise
  • Reported EPS: $-0.02
  • Estimate: $-0.23
  • Whisper: —
  • Surprise %: 91.3%
May 09, 2023
Mar 31, 2023 (Post market)
0.12 Surprise
  • Reported EPS: $0.29
  • Estimate: $0.17
  • Whisper: —
  • Surprise %: 70.6%
Feb 28, 2023
Dec 31, 2022 (Post market)
-0.25 Surprise
  • Reported EPS: $0.43
  • Estimate: $0.68
  • Whisper: —
  • Surprise %: -36.8%

Financials